ZUG, SWITZERLAND--(Marketwired - June 24, 2013) - Actavis, Inc. (NYSE: ACT), a leading
global specialty pharmaceutical company, today announced that it has
launched Sildenafil Actavis 25 mg, 50 mg and 100 mg tablets in 11 major
Western-European markets on market formation. Sildenafil Actavis, the
generic equivalent of Pfizer's Viagra®, is prescribed to treat
Actavis' product was launched immediately after the patents expired in
Austria, Denmark, France, Germany, Ireland, Italy, The Netherlands, Spain,
Sweden, Switzerland and the United Kingdom.
Actavis first launched Sildenafil tablets in Bulgaria in June 2009 - the
first generic Sildenafil to enter the patent-free Bulgarian market - and
has since launched the product in various other patent-free markets in
Europe, including Iceland and Malta. Sildenafil Actavis is manufactured
and developed by Actavis, in Malta and Iceland respectively.
According to IMS Health, Viagra® had sales of EUR382.2 million in
Europe for the 12 months ending March 31, 2013.
Actavis, Inc. (NYSE: ACT) is a global, integrated specialty pharmaceutical
company focused on developing, manufacturing and distributing generic,
brand and biosimilar products. Actavis has global headquarters in
Parsippany, New Jersey, USA.
Operating as Actavis Pharma, Actavis develops, manufactures and markets
generic, branded generic, legacy brands and Over-the-Counter (OTC) products
in more than 60 countries.
Actavis Specialty Brands is Actavis' global branded specialty
pharmaceutical business focused in the Urology and Women's Health
therapeutic categories. Actavis Specialty Brands also has a portfolio of
five biosimilar products in development in Women's Health and Oncology.
Actavis Global Operations has more than 30 manufacturing and distribution
facilities around the world, and includes Anda, Inc., a U.S. pharmaceutical
For press release and other company information, visit Actavis' Web site at
Statements contained in this press release that refer to non-historical
facts are forward-looking statements that reflect Actavis' current
perspective of existing information as of the date of this release. It is
important to note that Actavis' goals and expectations are not predictions
of actual performance. Actual results may differ materially from Actavis'
current expectations depending upon a number of factors, risks and
uncertainties affecting Actavis' business. These factors include, among
others, the impact of competitive products and pricing; the timing and
success of product launches; difficulties or delays in manufacturing; the
availability and pricing of third party sourced products and materials;
successful compliance with governmental laws, rules and regulations
applicable to Actavis and its third party manufacturers' facilities,
products and/or businesses; changes in the laws and regulations affecting
among other things, pricing and reimbursement of pharmaceutical products;
and such other risks and uncertainties detailed in Actavis' periodic public
filings with the Securities and Exchange Commission, including but not
limiting to Actavis' Quarterly Report on Form 10-Q for the quarter ended
March 31, 2013 and Actavis' annual report on Form 10-K for the year ended
December 31, 2012. Except as expressly required by law, Actavis disclaims
any intent or obligation to update these forward-looking statements.
Viagra® is a registered trademark of Pfizer, Inc.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Actavis via Thomson Reuters ONE